228 related articles for article (PubMed ID: 32671412)
1. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
[TBL] [Abstract][Full Text] [Related]
2. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
4. High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.
Lin YF; Tseng IJ; Kuo CJ; Lin HY; Chiu IJ; Chiu HW
J Cell Mol Med; 2018 Apr; 22(4):2458-2468. PubMed ID: 29392887
[TBL] [Abstract][Full Text] [Related]
5. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
6. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
7. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
8. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
9. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
Sha LY; Zhang Y; Wang W; Sui X; Liu SK; Wang T; Zhang H
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2201-8. PubMed ID: 27338043
[TBL] [Abstract][Full Text] [Related]
10. CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
Yi M; Peng C; Xia B; Gan L
Clin Breast Cancer; 2022 Feb; 22(2):e191-e198. PubMed ID: 34284965
[TBL] [Abstract][Full Text] [Related]
11. Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
Wen J; Yeo S; Wang C; Chen S; Sun S; Haas MA; Tu W; Jin F; Guan JL
Breast Cancer Res Treat; 2015 Feb; 149(3):619-29. PubMed ID: 25638397
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.
Liu M; Gong C; Xu R; Chen Y; Wang X
Cell Mol Biol Lett; 2019; 24():47. PubMed ID: 31308851
[TBL] [Abstract][Full Text] [Related]
13. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
Chou CW; Huang YM; Chang YJ; Huang CY; Hung CS
Int J Med Sci; 2021; 18(12):2521-2531. PubMed ID: 34104083
[TBL] [Abstract][Full Text] [Related]
14. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
15. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
16. MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway.
Fan YX; Dai YZ; Wang XL; Ren YQ; Han JJ; Zhang H
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2194-200. PubMed ID: 27338042
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of FOXO1‑mediated autophagy promotes paclitaxel‑induced apoptosis of MDA‑MB‑231 cells.
Xu K; Zhu W; Xu A; Xiong Z; Zou D; Zhao H; Jiao D; Qing Y; Jamal MA; Wei HJ; Zhao HY
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 35014689
[TBL] [Abstract][Full Text] [Related]
18. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
19. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
20. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
